INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44m ago
HOUSE PTR4m ago
SEC 13F4m ago
ROBINHOOD CHAIN4m ago
SEC FORM 4/Grant or awardVerified data

Flowers Cynthia Louise reported LSTA

Director · LISATA THERAPEUTICS, INC. · Common Stock

Side
A
Value
—
Shares
30.5K
Price
—
Executed
Jan 9, 2026
Disclosed
Jan 13, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jan 9 executedJan 13, 2026 disclosed

LSTA · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
17/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+9 / 25

No reported dollar value · 46.9% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · LSTA

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    21
    IT
    Imam TariqSVP, Bus Dev, General Counsel
    LSTALISATA THERAPEUTICS, INC.
    Grant or award
    		A—
    15.0K sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    IT
    Imam TariqSVP, Bus Dev, General Counsel
    LSTALISATA THERAPEUTICS, INC.
    Tax withholding
    		F$2,760
    1,401 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    IT
    Imam TariqSVP, Bus Dev, General Counsel
    LSTALISATA THERAPEUTICS, INC.
    Tax withholding
    		F$1,655
    840 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    IT
    Imam TariqSVP, Bus Dev, General Counsel
    LSTALISATA THERAPEUTICS, INC.
    Tax withholding
    		F$1,472
    747 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    IT
    Imam TariqSVP, Bus Dev, General Counsel
    LSTALISATA THERAPEUTICS, INC.
    Tax withholding
    		F$1,011
    513 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    IT
    Imam TariqSVP, Bus Dev, General Counsel
    LSTALISATA THERAPEUTICS, INC.
    Grant or award
    		A—
    7,000 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    21
    NJ
    Nisco JamesSVP, Fin/Treas, Chief Actg Off
    LSTALISATA THERAPEUTICS, INC.
    Grant or award
    		A—
    15.0K sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    13
    NJ
    Nisco JamesSVP, Fin/Treas, Chief Actg Off
    LSTALISATA THERAPEUTICS, INC.
    Tax withholding
    		F$4,198
    2,131 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    13
    NJ
    Nisco JamesSVP, Fin/Treas, Chief Actg Off
    LSTALISATA THERAPEUTICS, INC.
    Tax withholding
    		F$4,198
    2,131 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    NJ
    Nisco JamesSVP, Fin/Treas, Chief Actg Off
    LSTALISATA THERAPEUTICS, INC.
    Tax withholding
    		F$2,240
    1,137 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    NJ
    Nisco JamesSVP, Fin/Treas, Chief Actg Off
    LSTALISATA THERAPEUTICS, INC.
    Tax withholding
    		F$1,539
    781 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    NJ
    Nisco JamesSVP, Fin/Treas, Chief Actg Off
    LSTALISATA THERAPEUTICS, INC.
    Grant or award
    		A—
    7,000 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    17
    BK
    Buck Kristen KEVP, R&D and CMO
    LSTALISATA THERAPEUTICS, INC.
    Grant or award
    		A—
    25.0K sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    BK
    Buck Kristen KEVP, R&D and CMO
    LSTALISATA THERAPEUTICS, INC.
    Tax withholding
    		F$5,875
    2,982 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    BK
    Buck Kristen KEVP, R&D and CMO
    LSTALISATA THERAPEUTICS, INC.
    Tax withholding
    		F$5,875
    2,982 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    BK
    Buck Kristen KEVP, R&D and CMO
    LSTALISATA THERAPEUTICS, INC.
    Tax withholding
    		F$6,345
    3,221 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    BK
    Buck Kristen KEVP, R&D and CMO
    LSTALISATA THERAPEUTICS, INC.
    Tax withholding
    		F$4,230
    2,147 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    BK
    Buck Kristen KEVP, R&D and CMO
    LSTALISATA THERAPEUTICS, INC.
    Grant or award
    		A—
    13.0K sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001741455-26-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 9, 2026
    Published
    Jan 13, 2026
    Ingested by INSIDER
    Nov 5, 04:23 UTC
    Last re-read
    Nov 5, 04:23 UTC

    Extracted facts

    Filer
    Flowers Cynthia Louise
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    LISATA THERAPEUTICS, INC.
    Ticker
    LSTA
    Shares
    30.5K
    Price per share
    $0
    Execution date (reported)
    Jan 9, 2026
    Owned after transaction
    95.4K shares
    Days from execution to publication
    4

    What this establishes

    Flowers Cynthia Louise filed this Form 4 reporting a grant or award of LSTA on Jan 9, 2026. It became public on Jan 13, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Flowers Cynthia Louisecik:0001741455
    Issuer
    LISATA THERAPEUTICS, INC.cik:0000320017

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.